Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 353, Issue 3, 1996, Pages 355-362

  Toide, Katsuo ^a   Fujiwara, Takako ^a   Iwamoto, Yohko ^a   Shinoda, Masahiko ^a   Okamiya, Kazuhiro ^a   Kato, Takeshi ^b  

^a JAPAN TOBACCO INC   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Arginine vasopressin; Cerebral cortex; Hippocampus; JTP 4819; Prolyl endopeptidase; Substance P; Thyrotropin releasing hormone

Indexed keywords

ARGIPRESSIN; N BENZYL 2 [[2 (HYDROXYACETYL) 1 PYRROLIDINYL]CARBONYL] 1 PYRROLIDINECARBOXAMIDE; NEUROPEPTIDE; PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR; PROTIRELIN; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HIPPOCAMPUS; IMMUNOREACTIVITY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RAT;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; ANIMALS; ARGININE VASOPRESSIN; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; HIPPOCAMPUS; NEUROPEPTIDES; PYRROLIDINES; RATS; RATS, WISTAR; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SUBSTANCE P; THYROTROPIN-RELEASING HORMONE;

EID: 0029925283     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00168640     Document Type: Article

References (51)

1. Aoyagi T, Wada T, Nagai M, Kojima F, Harada S, Takeuchi T, Takahashi H, Hirokawa K, Tumita T (1990) Deficiency of kallikrein-like enzyme activities in cerebral tissue of patients with Alzheimer's disease. Experientia 46:94-97
2. Araujo DM, Lapchak PA, Robitaille Y, Gautheir S, Quirion R (1988) Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 50:1914-1923
3. Bartus RT, Dean III RL, Beer B, Lippa AS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217: 408-417
4. Beal MF, Mazurek MF (1987) Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex. Neurology 37:1205-1209
5. Biggins JA, Perry EK, Mcdermott JR, Smith AI, Perry RH, Edwardson JA (1983) Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression. J Neurol Sci 58:117-122
6. Coyle JT, Donald LP, Delong MR (1983) Alzheimer's disease; A disorder of cortical cholinergic innervation. Science 219:1184-1190
7. Crystal HA, Davies P (1982) Cortical Substance P-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. J Neurochem 38:1781-1784
8. Dalmaz C, Netto CA, Volkmer N, Dias RD, Izquierdo I (1986) Distribution of proline endopeptidase activity in sub-synaptosomal fractions of rat hypothalamus. Brazilian J Med Biol Res 19:685-690
9. De Wied D (1984) The importance of vasopressin in memory. Trends Neurosci 7:62-64
10. De Wied D, Gaffori O, Ree JM, Jong W (1984) Central target for the behavioral effects of vasopressin neuropeptides. Nature 308:276-280
11. Dresdner K, Barker LA, Orlowski M, Wilk S (1982) Subcellular distribution of prolyl endopeptidase and cation-sensitive neutral endopeptidase in rabbit brain. J. Neurochem 38:1151-1154
12. Faden AI, Salzman S (1992) Pharmacological strategies in CNS trauma. Trends Pharmacol Sci 13:29-35
13. Ferrier IN, Cross AJ, Johnson JA, Roberts GW, Crow TJ, Corsellis JAN, Lee YC, O'shaughnessy D, Adrian TE, Mcgregor GP, Baracese-Hamilton AJ, Bloom SR (1983) Neuropeptides in Alzheimer type dementia. J Neurol Sci 62:159-170
14. Fujiyoshi K, Suga H, Okamoto K, Nakamura S, Kameyama M (1987) Reduction of arginine-vasopressin in the cerebral cortex in Alzheimer type senile dementia. J Neurol Neurosurg Psychiatry 50:929-932
15. Griffiths EC (1987) Clinical applications of thyrotropin-releasing hormone. Clin Sci 73:449-457
16. Griffiths EC, Baris C, Visser TJ, Klootwijk W (1985) Thyrotropin-releasing hormone inactivation by human postmortem brain. Regul Pept 10:145-155
17. Hasenöhrl RU, Huston JP, Schuurman T (1990) Neuropeptide substance P improves water maze performance in aged rats. Psychopharmacology 101:23-26
18. Husain MM, Nemeroff CB (1990) Neuropeptides and Alzheimer's disease. J Am Geriatr Soc 38:918-925
19. Huston JP, Hasenohrl RU, Gerhardt P, Schwarting RKW (1993) Sequence-specific effects of neurokinin substance P on memory, reinforcement and brain dopamine activity. Psychopharmacology 112:147-162
20. Ishiura S, Tsukahara T, Tabira T, Shimizu T, Arahata K, Sugita H (1990) Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase. FEBS Lett 260:131-134
21. Kalwant S, Porter AG (1991) Purification and characterization of human brain prolyl endopeptidase. Biochem J 276:237-244
22. Kato T, Inomata Y, Takeda K (1993) Determination of the axonally transported substance P-like imunoreactivity in rat sciatic nerves with a newly developed E1A method. Neurochem Res 18:818
23. Knisatschek H, Bauer K (1986) Specific inhibition of post proline cleaving enzyme by benzyloxycarbonyl-Gly-Pro-Diazomethyl ketone. Biochem Biophys Res Commun 134:888-894
24. Koida M, Walter R (1976) Post-proline cleaving enzyme. J Biol Chem 251:7593-7599
25. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA (1991) An in vivo model for the neurogenerative effects of β-amyloid and protection by Substance P. Proc Natl Acad Sci USA 88:7247-7251
26. Lippa AS, Pelham RW, Beer B, Critchett DJ, Dean RL, Bartus RT (1980) Brain cholinergic dysfunction and memory in aged rats. Neurobiol Aging 1:13-19
27. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275
28. Mazurek MF, Beal MF, Martin JB (1985) Vasopressin in postmortem Alzheimer brain. Ann Neurol 18:143
29. Mazurek MF, Beal MF, Bird FD, Martin JB (1986) Vasopressin in Alzheimer's disease: A study of postmortem brain concentrations. Ann Neurol 20:665-670
30. O'leary RM, O'connor B (1995) Identification and localisation of a synaptosomal membrane prolyl endopeptidase from bovine brain. Eur J Biochem 227:277-283
31. Oram J, Edwardson J, Millard P (1981) Investigation of cerebrospinal fluid neuropeptides in idiopathic senile dementia. Gelontology 27:216-223
32. Perry EK (1986) The cholinergic hypothesis. Ten years on. Br Med Bull 42:63-69
33. Rossor MN, Emson PC, Dawbarn D, Mountjoy CQ, Roth M (1986) Neuropeptides and dementia. Progr Brain Res 66: 143-159
34. Sarter M (1991) Taking stock of cognition enhancers. Trends Pharmacol Sci 12:456-461
35. Schlesinger K, Lipsitz DU, Peck PL, Pelleymounter MA, Stewart JM, Chase TN (1983) Substance P enhancement of passive and active avoidance conditioning in mice. Pharmacol Biochem Behav 19:655-661
36. Selkoe DJ (1989) Aging, amyloid, and Alzheimer's disease. N Engl J Med 320:1484-1487
37. Selkoe DJ (1990) Deciphering Alzheimer's disease: the amyloid precursor protein yields new clues. Science 248:1058-1060
38. Suzuki H, Yoshioka M, Yanagisawa M, Urayama O, Kurihara T, Hosoki R, Saito K, Otsuka M (1994) Involvement of enzymatic degradation in the inactivation of tachykinin neurotransmitters in neonatal rat spinal cord. Br J Pharmacol 113:310-316
39. Taira K, Kaneto H (1987) Experimental models for studying the avoidance response in mice and the anti-amnesic effect of prolylendopeptidase inhibitors. Folia Pharmacol Jpn (in Japanese) 89:243-252
40. Taylor WL, Dixon JE (1980) Catabolism of neuropeptides by a brain proline endopeptidase. Biochem Biophys Res Commun 94:9-15
41. Toide K, Shinoda M, Uemura A (1994) Effect of JTP-4819, a novel prolyl endopeptidase (PEP) inhibitor, on passive avoidance response and Morris water maze task. Jpn J Psychopharmacol 14:454 [Suppl]
42. Toide K, Iwamoto Y, Fujiwara T, Abe H (1995a) JTP-4819: A novel prolyl endopeptidase inhibitor with potential as a congnitive enhancer. J Pharmacol Exp Ther 274:1370-1378
43. Toide K, Okamiya K, Iwamoto Y, Kato T (1995b) Effect of a novel prolyl endopeptidase inhibitor. JTP-4819. on PEP activity and substance P- and arginine-vasopressin-like immunoreactivity in the brains of aged rats. J Neurochem 65:234-240
44. Walter R, Shlank H, Glass JD, Schwartz IL, Kerenyi TD (1971) Leucylglycinamide released from oxytocin by human enzyme. Science 173:827-829
45. Walter R, Simmons WH, Yoshimoto T (1980) Proline specific endo-and exopeptidases. Mol Cell Biochem 30:111-127
46. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delong MR (1982) Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain. Science (Wash. DC) 215: 1237-1239
47. Wilk S (1983) Mini review prolyl endopeptidase. Life Sci 33: 2149-2157
48. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotropic and neurotoxic effects of amyloid β-protein: reversal by tachykinin neuropeptides. Science 250:279-282
49. Yoshimoto T (1991) Proline specific peptidases and their specific inhibitors. Yakugaku Zasshi (in Japanese) 111:345-358
50. Yoshimoto T, Ogita K, Walter R, Koida M, Tsuru O (1979) Synthesis of a new fluorogenic substrate and distribution of the endopeptidase in rat tissues and body fluids of man. Biochim Biophys Acta 569:184-192
51. Yoshimoto T, Nishimura T, KITA T, Tsuru D (1983) Post-proline cleaving enzyme (Prolyl endopeptidase) from bovine brain. J. Biochem 94:1179-1190